

30 November 2009

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products listed in the Invitation to Tender dated 21 December 2007 and the Invitation to Tender dated 23 December 2008.

Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly.

Product Notification Forms

Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) suppliers are required to notify PHARMAC and the Guild by 4pm **11th December 2009**. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp.

2008/09 Tender

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to listed pharmaceuticals where no other brand is listed – Sole Subsidised Supply commences on **1 April 2010**.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Current Subsidy | New tender subsidy | Sole supply brand (Supplier) |
|---------------|----------------------------------|-----------------|--------------------|------------------------------|
| Tropisetron | Cap 5 mg; 5 capsules, blister | \$77.41 | \$77.41 | Navoban (Novartis) |

2. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on **1 January 2010**, reference pricing of non-tender winning brand will occur on **1 March 2010** and Sole Subsidised Supply commences on **1 June 2010**.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Current subsidy | New tender subsidy | Sole supply brand (Supplier) | Brands affected by reference pricing and delisting |
|--------------------------|--|-----------------|--------------------|------------------------------|--|
| Flucloxacillin sodium* | Cap 250 mg; 250 capsules, bottle | \$18.50 | \$32.00 | AFT (AFT) | Staphlex (Mylan) |
| Flucloxacillin sodium* | Cap 500 mg; 500 capsules, bottle | \$57.90 | \$110.00 | AFT (AFT) | Staphlex (Mylan) |
| Paracetamol with codeine | Tab paracetamol 500 mg with codeine phosphate 8 mg; 100 tablets, blister | \$3.24 | \$2.45 | ParaCode (Arrow) | Codalgin (Sigma) |
| Pindolol* | Tab 5 mg; 100 tablets, bottle | \$4.50 | \$5.40 | Apo-Pindolol (Apotex) | Pindol (Mylan) |
| Pindolol* | Tab 10 mg; 100 tablets, bottle | \$8.35 | \$9.19 | Apo-Pindolol (Apotex) | Pindol (Mylan) |
| Pindolol* | Tab 15 mg; 100 tablets, bottle | \$12.00 | \$13.80 | Apo-Pindolol (Apotex) | Pindol (Mylan) |

*Reference pricing will not be applied

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to listed pharmaceuticals where only the current brand is listed – DV Limits and DV Pharmaceuticals will apply from **1 March 2010**.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Hospital Supply Brand (Supplier) | Pack Price | DV Limit | DV Pharmaceuticals Brand Name (Supplier) |
|---------------|----------------------------------|----------------------------------|------------|----------|--|
| Tropisetron | Cap 5 mg; 5 capsules, blister | Navoban (Novartis) | \$77.41 | 1% | (B) |

4. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – listing for hospital tender winning brands of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 January 2010**; DV Limits and DV pharmaceuticals will apply from **1 March 2010**; de-listing of other brands in Section H will occur on **1 March 2010**.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Hospital Supply Brand (Supplier) | Pack Price | DV Limit | DV Pharmaceuticals Brand Name (Supplier) |
|-----------------------|----------------------------------|----------------------------------|------------|----------|--|
| Flucloxacillin sodium | Cap 250 mg; 250 capsules, bottle | AFT (AFT) | \$32.00 | 1% | Staphlex (Mylan) |
| Flucloxacillin sodium | Cap 500 mg; 500 capsules, bottle | AFT (AFT) | \$110.00 | 1% | Staphlex (Mylan) |

5. Tenders awarded to pharmaceuticals where no brand is listed - listing of the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 January 2010** and DV Limits and DV Pharmaceuticals will apply from **1 March 2010**.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Hospital Supply Brand (Supplier) | Pack Price | DV Limit | DV Pharmaceuticals Brand Name (Supplier) |
|---------------|----------------------------------|----------------------------------|------------|----------|--|
| Pindolol | Tab 5 mg; 100 tablets, bottle | Apo-Pindolol (Apotex) | \$5.40 | 1% | Pindol (Mylan) |
| Pindolol | Tab 10 mg; 100 tablets, bottle | Apo-Pindolol (Apotex) | \$9.19 | 1% | Pindol (Mylan) |
| Pindolol | Tab 15 mg; 100 tablets, bottle | Apo-Pindolol (Apotex) | \$13.80 | 1% | Pindol (Mylan) |

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 23 December 2008.

The decisions were as follows:

| Chemical Name | Line Item |
|--------------------------------|-----------------------------------|
| Aciclovir | Tab 200 mg |
| Aciclovir | Tab 400 mg |
| Aciclovir | Tab 800 mg |
| Aciclovir | Tab dispersible 200 mg |
| Aciclovir | Tab dispersible 400 mg |
| Aciclovir | Tab dispersible 800 mg |
| Diclofenac Sodium | Tab long-acting 75 mg |
| Diclofenac Sodium | Tab long-acting 100 mg |
| Hydrocortisone with Miconazole | Crn 1% with miconazole nitrate 2% |
| Leflunomide | Tab 10 mg |
| Leflunomide | Tab 20 mg |

| Chemical Name | Line Item |
|------------------------|-----------------------|
| Leflunomide | Tab 100 mg |
| Mucilaginous Laxatives | Sugar Free |
| Mupirocin | Oint 2% |
| Tropisetron | Inj 1 mg per ml, 2 ml |

2007/08 Tender

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 21 December 2007.

The decisions were as follows:

| Chemical Name | Line Item |
|-------------------------|--|
| Ceftriaxone Sodium | Inj 500 mg |
| Ceftriaxone Sodium | Inj 1 g |
| Ceftriaxone Sodium | Inf 2 g |
| Dexamethasone | Eye drops 0.1% |
| Dexamethasone | Tab 0.5 mg |
| Dexamethasone | Tab 1 mg |
| Dexamethasone | Tab 4 mg |
| Gentamicin Sulphate | Powder BP |
| Hydrocortisone Butyrate | Crm 0.1% (pack size greater than 30 g) |
| Tamsulosin | Tab 400 mcg |
| Tobramycin | Powder BP |

For the remaining products on the Invitation to Tender dated 21 December 2007 and the Invitation to Tender dated 23 December 2008 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock.

We will keep you informed regarding any changes for the remaining tender products as further decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.